Global pharmaceutical market is expected to grow in the upcoming years despite recent slowdown in key markets across the globe. The reasons are simple: aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases.

Global pharmaceuticals market is expected to be worth USD 1.57 trillion by 2023.

As per NAVADHI Market Research, the global pharmaceutical industry will be worth **USD 1.57 trillion** by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

North America is expected to retain its leading position in the global pharmaceuticals market with market share of 45.33% in 2023 improving on its market share compared to 2017. Europe on the contrary is expected to see a decline in its market share compared to 2017 and be worth 20.24% of global pharma industry in 2023. Asia Pacific pharmaceuticals market is expected to retain its second position with a market share of 24.07% in 2023. Latin America and Middle East and Africa (MEA) are expected to retain 7.53% and 2.96% market share of global pharmaceuticals market in 2023.

This growth is fuelled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global pharma industry. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and speciality diseases market. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies...
and bioelectronics & implantables has attracted investments in the industry by even non-pharma companies like Facebook, Qualcomm etc. which is also driving the global pharmaceuticals industry growth.

On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the global pharma market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug. Apart from this generics pharma market is facing decreasing return on investment due to price erosion in key markets which is forcing many firms to look for other avenues and markets to sustain growth.


Global Pharmaceuticals Industry Analysis and Trends 2023 report covers growth forecasts for 39 countries along with 5 major geographic regions.

1. In the Asia Pacific region growth forecasts are provided for Australia, China, India, Japan and South Korea.
2. In the Europe region growth forecasts are provided for France, Germany, Italy, Russia, Spain and United Kingdom.
3. In the Middle East and Africa (MEA) region growth forecasts are provided for Algeria, Bahrain, Cote d'Ivoire (Ivory Coast), Egypt, Jordan, Kenya, Kuwait, Lebanon, Morocco, Saudi Arabia, Senegal, South Africa, Tunisia, Turkey and UAE.
4. In the Latin America region growth forecasts are provided for Bolivia, Brazil, Costa Rica, Chile, Colombia, Dominican Republic, Ecuador, Mexico, Paraguay, Peru and Uruguay.
5. In the North America region growth forecasts are provided for Canada and USA.
This report also covers therapy-wise forecast for 15 key therapy areas (Antianemic, Anticoagulant, Antidiabetics, Antifibrinolytic, Antihyperlipidemic, Antihypertensive, Antirheumatics, Antiviral, Bronchodilators, Dermatological, Immunosuppressants, Multiple Sclerosis (MS), Oncology, Sensory Organ and Vaccine) in global pharmaceuticals market.

Research Methodology

1. Executive Summary

Scope of the Global Pharmaceuticals Industry Analysis and Trends 2023 Report
2. Introduction of Global Pharmaceuticals Market

Key Product Terms Used in Pharmaceuticals Industry
- Pharmaceuticals
- Innovative Drugs
- Orphan Drugs
- Generic Drugs
- Commodity Generic Drugs
- Branded Generic Drugs
- Biologics
- Biosimilars
- Over-the-counter (OTC) Drugs
- Active Pharmaceutical Ingredients (APIs)
- Excipients

Research and Development (R&D) Phases of Pharmaceuticals Industry
- Industry-Wise Research and Development (R&D) Investment
- Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
- Global Pharmaceuticals Industry Value Chain Analysis

3. Need for Global Pharmaceuticals Market

Rising & Ageing Global Population
- Increasing Income Levels of Poor & Middle-Class Families

4. Forecast for Global Pharmaceuticals Market 2023

4.1 Geography-Wise Market Share of Global Pharmaceuticals Market in 2017
4.2 Geography-Wise CAGR Growth Forecast for Global Pharmaceuticals Market 2018-2023
4.3 Forecast for Global Pharmaceuticals Market 2018-2023
4.4 Geography-Wise Market Share of Global Pharmaceuticals Market in 2023
4.5 Forecast for Asia Pacific Pharmaceuticals Market 2018-2023
4.5.1 Forecast for Australia Pharmaceuticals Market 2018-2023
4.5.2 Forecast for China Pharmaceuticals Market 2018-2023
4.5.3 Forecast for India Pharmaceuticals Market 2018-2023
4.5.4 Forecast for Japan Pharmaceuticals Market 2018-2023
4.5.5 Forecast for South Korea Pharmaceuticals Market 2018-2023
4.5.6 Forecast for Rest of Asia Pacific Pharmaceuticals Market 2018-2023
4.6 Forecast for Europe Pharmaceuticals Market 2018-2023
4.6.1 Forecast for France Pharmaceuticals Market 2018-2023
4.6.2 Forecast for Germany Pharmaceuticals Market 2018-2023
4.6.3 Forecast for Italy Pharmaceuticals Market 2018-2023
4.6.4 Forecast for Russia Pharmaceuticals Market 2018-2023
4.6.5 Forecast for Spain Pharmaceuticals Market 2018-2023
4.6.6 Forecast for United Kingdom Pharmaceuticals Market 2018-2023
4.6.7 Forecast for Rest of Europe Pharmaceuticals Market 2018-2023
4.7 Forecast for Middle East and Africa (MEA) Pharmaceuticals Market 2018-2023
4.7.1 Forecast for Algeria Pharmaceuticals Market 2018-2023
4.7.2 Forecast for Bahrain Pharmaceuticals Market 2018-2023
4.7.3 Forecast for Cote d’Ivoire (Ivory Coast) Pharmaceuticals Market 2018-2023
4.7.4 Forecast for Egypt Pharmaceuticals Market 2018-2023
4.7.5 Forecast for Jordan Pharmaceuticals Market 2018-2023
4.7.6 Forecast for Kenya Pharmaceuticals Market 2018-2023
4.7.7 Forecast for Kuwait Pharmaceuticals Market 2018-2023
4.7.8 Forecast for Lebanon Pharmaceuticals Market 2018-2023
4.7.9 Forecast for Morocco Pharmaceuticals Market 2018-2023
4.7.10 Forecast for Saudi Arabia Pharmaceuticals Market 2018-2023
4.7.11 Forecast for Senegal Pharmaceuticals Market 2018-2023
4.7.12 Forecast for South Africa Pharmaceuticals Market 2018-2023
4.7.13 Forecast for Tunisia Pharmaceuticals Market 2018-2023
4.7.14 Forecast for Turkey Pharmaceuticals Market 2018-2023
4.7.15 Forecast for UAE Pharmaceuticals Market 2018-2023
4.7.16 Forecast for Rest of Middle East and Africa (MEA) Pharmaceuticals Market 2018-2023

4.8 Forecast for Latin America Pharmaceuticals Market 2018-2023
4.8.1 Forecast for Bolivia Pharmaceuticals Market 2018-2023
4.8.2 Forecast for Brazil Pharmaceuticals Market 2018-2023
4.8.3 Forecast for Costa Rica Pharmaceuticals Market 2018-2023
4.8.4 Forecast for Chile Pharmaceuticals Market 2018-2023
4.8.5 Forecast for Colombia Pharmaceuticals Market 2018-2023
4.8.6 Forecast for Dominican Republic Pharmaceuticals Market 2018-2023
4.8.7 Forecast for Ecuador Pharmaceuticals Market 2018-2023
4.8.8 Forecast for Mexico Pharmaceuticals Market 2018-2023
4.8.9 Forecast for Paraguay Pharmaceuticals Market 2018-2023
4.8.10 Forecast for Peru Pharmaceuticals Market 2018-2023
4.8.11 Forecast for Uruguay Pharmaceuticals Market 2018-2023
4.8.12 Forecast for Rest of Latin America Pharmaceuticals Market 2018-2023

4.9 Forecast for North America Pharmaceuticals Market 2018-2023
4.9.1 Forecast for Canada Pharmaceuticals Market 2018-2023
4.9.2 Forecast for USA Pharmaceuticals Market 2018-2023

4.10 Therapy-Wise Forecast For Global Pharmaceuticals Market in 2023
4.10.1 Forecast for Global Antianemic Pharmaceuticals Market 2018-2023
4.10.2 Forecast for Global Anticoagulants Pharmaceuticals Market 2018-2023
4.10.3 Forecast for Global Antidiabetics Pharmaceuticals Market 2018-2023
4.10.4 Forecast for Global Antifibrinolytics Pharmaceuticals Market 2018-2023
4.10.5 Forecast for Global Antihyperlipidemias Pharmaceuticals Market 2018-2023
4.10.6 Forecast for Global Antihypertensive Pharmaceuticals Market 2018-2023
4.10.7 Forecast for Global Antirheumatics Pharmaceuticals Market 2018-2023
4.10.8 Forecast for Global Anti-Virals Pharmaceuticals Market 2018-2023
4.10.9 Forecast for Global Bronchodilators Pharmaceuticals Market 2018-2023
4.10.10 Forecast for Global Dermatologicals Pharmaceuticals Market 2018-2023
4.10.11 Forecast for Global Immunosuppressants Pharmaceuticals Market 2018-2023
4.10.12 Forecast for Global Multiple Sclerosis (MS) Pharmaceuticals Market 2018-2023
4.10.13 Forecast for Global Oncology Pharmaceuticals Market 2018-2023
4.10.14 Forecast for Global Sensory Organs Pharmaceuticals Market 2018-2023
4.10.15 Forecast for Global Vaccines Pharmaceuticals Market 2018-2023
4.10.16 Forecast for Global Rest of Therapy Areas Pharmaceuticals Market 2018-2023

5. Growth Drivers and Inhibitors for Global Pharmaceuticals Market

6. Risks Associated with Global Pharmaceuticals Market

6.1 Risk of Patent Expiry and Loss of Intellectual Property Protection
6.2 Risk of Commercial Success of New Products  
6.3 Risk of Failed Research and Development Effort  
6.4 Risk of Drug Price Controls  
6.5 Risk of Failure to Comply with New Laws and Regulations  
6.6 Risk of Quality Control During Complex Manufacturing Process  
6.7 Risk of Cyber-Attacks and Data Breach  
6.8 Risk of Volatile Currency Exchange Rates and Interest Rates  
6.9 Risk of Unstable Global Political and Economic Conditions

7. Industry Associations Related to Global Pharmaceuticals Market

7.1 European Federation of Pharmaceutical Industries and Associations (EFPIA)  
7.2 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)  
7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)  
7.4 Association of the British Pharmaceutical Industry (ABPI)  
7.5 Japan Pharmaceutical Manufacturers Association (JPMA)  
7.6 Indian Drug Manufacturers' Association (IDMA)

8. Profile of Key Players in Global Pharmaceuticals Market

8.1 Pfizer Inc.
     8.1.1 Company Profile  
     8.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain  
     8.1.3 Pfizer Inc.: Financial Performance  
     8.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)  
     8.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)  
     8.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)  
     8.1.4 Pfizer Inc.: Business Strategy  
     8.1.4.1 Product Level Strategy  
     8.1.5 SWOT Analysis of Pfizer Inc.  
        Strengths  
        Weaknesses  
        Opportunities  
        Threats

8.2 Novartis International AG
     8.2.1 Company Profile  
     8.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain  
     8.2.3 Novartis AG: Financial Performance  
     8.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)  
     8.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)  
     8.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)  
     8.2.4 Novartis AG: Business Strategy  
     8.2.5 SWOT Analysis of Novartis International AG  
        Strengths  
        Strengths  
        Weaknesses  
        Opportunities  
        Threats

8.3 Johnson & Johnson
     8.3.1 Company Profile  
     8.3.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
8.3.3 Johnson & Johnson Financial Performance
8.3.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.3.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)
8.3.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)
8.3.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.3.4 Johnson & Johnson: Business Strategy
8.3.4.1 Product Level Business Strategy
8.3.5 Johnson & Johnson’s Pharmaceutical Division Growth Drivers
8.3.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats

8.4 GlaxoSmithKline PLC
8.4.1 Company Profile
8.4.2 GlaxoSmithKline Plc in Global Pharmaceuticals Manufacturing Value Chain
8.4.3 GlaxoSmithKline Plc: Financial Performance
8.4.3.1 GlaxoSmithKline Plc: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 GlaxoSmithKline Plc: Division-Wise Revenue FY 2018 (in USD billion)
8.4.3.3 GlaxoSmithKline Plc: Geography-Wise Revenue FY 2018 (in USD billion)
8.4.3.4 GlaxoSmithKline Plc: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.4.4 GlaxoSmithKline Plc: Business Strategy
8.4.4.1 Product Level Strategy
8.4.5 SWOT Analysis of GlaxoSmithKline Plc
Strengths
Weaknesses
Opportunities
Threats

8.5 Roche Holding AG
8.5.1 Company Profile
8.5.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
8.5.3 Roche Holding AG: Financial Performance
8.5.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
8.5.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
8.5.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
8.5.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
8.5.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
8.5.4 Roche Holding AG: Business Strategy
8.5.4.1 Product Level Strategy
8.5.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats

8.6 Merck & Co. Inc.
8.6.1 Company Profile
8.6.2 Merck & Co. Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.6.3 Merck & Co. Inc.: Financial Performance
8.6.3.1 Merck & Co. Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.6.3.2 Merck & Co. Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.6.3.3 Merck & Co. Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.6.3.4 Merck & Co. Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.6.4 Business Strategy of Merck & Co. Inc.
8.6.4.1 Product Level Strategy
8.6.5 SWOT Analysis of Merck & Co. Inc.

Strengths
Weaknesses
Opportunities
Threats

8.7 Sanofi S.A.
8.7.1 Company Profile
8.7.2 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
8.7.3 Sanofi S.A.: Financial Performance (in Euro millions)
8.7.3.1 Sanofi S.A.: Geography-Wise Revenue (in Euro millions)
8.7.4 Sanofi S.A.: Business Strategy
8.7.4.1 Sanofi S.A. Revenue by Global Business Units (GBU’s)
8.7.4.2 Sanofi S.A. Revenue by Global Franchise
8.7.5 SWOT Analysis of Sanofi S.A.

Strengths
Weaknesses
Opportunities
Threats

8.7.6 Sanofi’s TOP 10 Blockbusters Drugs Revenue in FY 2018 (in Euro millions)

8.8 AbbVie Inc.
8.8.1 Company Profile
8.8.2 AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.8.3 AbbVie Inc.: Financial Performance
8.8.3.1 AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.8.3.2 AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.8.3.3 AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.8.4 AbbVie Inc.: Business Strategy
8.8.4.1 Product Level Strategy
8.8.5 SWOT Analysis of AbbVie Inc.

Strengths
Weaknesses
Opportunities
Threats

8.9 Gilead Sciences Inc.
8.9.1 Company Profile
8.9.2 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.9.3 Gilead Sciences, Inc.: Financial Performance
8.9.4 Gilead Sciences, Inc.: Geography wise Performance
8.9.5 Gilead Sciences, Inc.: Business Strategy
8.9.6 SWOT Analysis of Gilead Sciences, Inc.

Strengths
Weaknesses
Opportunities
Threats

8.10 Bayer AG
8.10.1 Company Profile
8.10.2 Bayer in Global Pharmaceuticals Manufacturing Value Chain
8.10.3 Bayer: Financial Performance
8.10.3.1 Bayer: Overall Revenue FY 2013-FY 2019 (in Euro billion)
8.10.3.2 Bayer: Division-Wise Revenue FY 2018 (in Euro billion)
8.10.3.3 Bayer: Geography-Wise Revenue FY 2018 (in Euro billion)
8.10.3.4 Bayer: Best Selling Pharmaceutical Products Revenue FY 2018 (in Euro billion)
8.10.3.5 Bayer: Best Selling Consumer Health Products Revenue FY 2018 (in Euro billion)
8.10.3.6 Bayer: Crop Science Segment-Wise Revenue FY 2018 (in Euro billion)
8.10.3.7 Bayer: Best Selling Animal Health Products Revenue FY 2018 (in Euro billion)
8.10.4 Bayer AG: Business Strategy
8.10.4.1 Product Level Strategy
8.10.5 SWOT Analysis of Bayer AG
Strengths
Weaknesses
Opportunities
Threats

9. Competitive Landscape in Global Pharmaceuticals Market

9.1 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Overall Revenue
9.2 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Global Pharmaceuticals Revenue
9.3 Competitive Landscape Among Top 10 Pharmaceuticals Companies by United States Pharmaceuticals Revenue
9.4 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Research and Development (R&D) Expenditure
9.5 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Earning Per Share (EPS)
9.6 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
9.7 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Overall Revenue Forecast
9.8 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Top 3 Product Revenues

10. Analysis of Global Pharmaceuticals Market

10.1 Porter’s Five Forces Analysis of Global Pharmaceuticals Market
10.2 SWOT Analysis of Global Pharmaceuticals Market
Strengths
Weaknesses
Opportunities
Threats

11. Current and Future Trends in Global Pharmaceuticals Market

List of Exhibits
Notes
Company Information

List of Exhibits

Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 Global Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
Exhibit 4.93 Colombia Pharmaceuticals Market Analysis
Exhibit 4.94 Forecast for Colombia Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.95 Population Forecast for Costa Rica 2016-2023 (in millions)
Exhibit 4.96 Costa Rica Pharmaceuticals Market Analysis
Exhibit 4.97 Forecast for Costa Rica Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.98 Population Forecast for Dominican Republic 2016-2023 (in millions)
Exhibit 4.99 Forecast for Dominican Republic Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.100 Population Forecast for Ecuador 2016-2023 (in millions)
Exhibit 4.101 Forecast for Ecuador Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.102 Population Forecast for Mexico 2016-2023 (in millions)
Exhibit 4.103 Mexico Pharmaceuticals Market Analysis
Exhibit 4.104 Forecast for Mexico Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.105 Population Forecast for Paraguay 2016-2023 (in millions)
Exhibit 4.106 Forecast for Paraguay Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.107 Population Forecast for Peru 2016-2023 (in millions)
Exhibit 4.108 Forecast for Peru Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.109 Population Forecast for Uruguay 2016-2023 (in millions)
Exhibit 4.110 Forecast for Uruguay Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.111 Forecast for Rest of Latin America Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.112 Forecast for North America Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.113 Country-wise Market Share in North America Pharmaceuticals Market in 2017 (in %)
Exhibit 4.115 Population Forecast for Canada 2016-2023 (in millions)
Exhibit 4.116 Canada Pharmaceuticals Market Analysis
Exhibit 4.117 Forecast for Canada Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.118 Population Forecast for USA 2016-2023 (in millions)
Exhibit 4.119 USA Pharmaceuticals Market Analysis
Exhibit 4.120 Forecast for USA Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.121 Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
Exhibit 4.122 Therapy Area-wise CAGR Growth Forecast for Global Pharmaceuticals Market 2018-2023 (in %)
Exhibit 4.123 Forecast for Global Antianemic Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.124 Forecast for Global Anticoagulants Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.125 Forecast for Global Antidiabetics Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.126 Forecast for Global Antifibrinolytics Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.127 Forecast for Global Antihyperlipidemias Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.128 Forecast for Global Antihypertensive Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.129 Forecast for Global Antiinfectives Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.130 Forecast for Global Anti-Virals Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.131 Forecast for Global Bronchodilators Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.132 Forecast for Global Dermatologicals Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.133 Forecast for Global Immunosuppressants Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.134 Forecast for Global Multiple Sclerosis (MS) Therapies Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.135 Forecast for Global Oncology Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.136 Forecast for Global Sensory Organs Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.137 Forecast for Global Vaccines Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.138 Forecast for Global Rest of Therapy Areas Pharmaceuticals Market 2018-2023 (in USD billion)
billion)

Exhibit 5.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 7.1 Key Information of EFPIA
Exhibit 7.2 Contact details of EFPIA
Exhibit 7.3 List of EFPIA Members
Exhibit 7.4 Key Information of IFPMA
Exhibit 7.5 Contact details of IFPMA
Exhibit 7.6 List of IFPMA Members
Exhibit 7.7 Key Information of PhRMA
Exhibit 7.8 Contact details of PhRMA
Exhibit 7.9 List of PhRMA Members
Exhibit 7.10 Key information of ABPI
Exhibit 7.11 Contact details of ABPI
Exhibit 7.12 List of ABPI Members
Exhibit 7.13 Key Information of JPMA
Exhibit 7.14 Key Information of JPMA
Exhibit 7.15 List of JPMA Members
Exhibit 7.16 Key information of IDMA
Exhibit 7.17 Contact details of IDMA
Exhibit 8.1 Key Information of Pfizer Inc.
Exhibit 8.2 Contact information of Pfizer Inc.
Exhibit 8.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 8.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)
Exhibit 8.9 SWOT Analysis of Pfizer Inc.
Exhibit 8.10 Key Information of Novartis AG
Exhibit 8.11 Contact Information of Novartis AG
Exhibit 8.12 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.13 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 8.14 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 8.15 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 8.16 Therapy and Geography Area-Wise Revenue of Novartis AG FY 2018 (in USD million)
Exhibit 8.17 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 8.18 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.19 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.20 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.21 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 8.22 SWOT Analysis of Novartis AG
Exhibit 8.23 Key Information of Johnson & Johnson
Exhibit 8.24 Contact information of Johnson & Johnson
Exhibit 8.25 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.26 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 8.27 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 8.28 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.29 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.30 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.31 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.132 Consumer Health Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 8.133 Crop Science Division Revenue of Bayer FY 2013- FY 2018 (in USD billion)
Exhibit 8.134 Crop Science Division Revenue of Bayer FY 2013- FY 2018 (in USD billion)
Exhibit 8.135 Geography-Wise Revenue of Bayer in FY 2018 (in Euro billion)
Exhibit 8.136 Best Selling Pharmaceuticals Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 8.137 Best Selling Consumer Health Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 8.138 Crop Science Segment-Wise Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 8.139 Best Selling Animal Health Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 8.140 Bayer's Research and Development Projects (Phase II) as of January 31, 2019
Exhibit 8.141 Bayer's Research and Development Projects (Phase III) as of January 31, 2019
Exhibit 8.142 Bayer's Main Products Submitted for Approval as of January 31, 2019
Exhibit 8.143 SWOT Analysis of Bayer AG
Exhibit 9.1 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Overall Revenue for FY2018 (in USD billion)
Exhibit 9.2 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.3 Competitive Landscape Among Top 10 Pharmaceuticals Companies by United States Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.4 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
Exhibit 9.5 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
Exhibit 9.6 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
Exhibit 9.7 Competitive Landscape Among Top 10 Pharmaceuticals Companies by Overall Revenue Forecast for FY2019 (in USD billion)
Exhibit 9.8 Competitive Landscape Among Top 10 Pharmaceuticals Companies by 3 Blockbuster Product Revenue for FY2018 (in USD billion)
Exhibit 10.1 Porter’s Five Forces Analysis for Global Pharmaceuticals Market
Exhibit 10.2 SWOT Analysis for Global Pharmaceuticals Market

1. Pfizer Inc.
2. Novartis International AG
3. Johnson & Johnson
4. GlaxoSmithKline PLC
5. Roche Holding AG
7. Sanofi S.A.
8. AbbVie Inc.
9. Gilead Sciences Inc.
10. Bayer AG

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person
that wishes to use the publication within the same organization.

- Customers who infringe these license terms are liable for a Enterprise license fee.

**Site License (PDF)**

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

**Enterprise License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

**About Us**

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

**Information**

- [About Us](#)
- [Publications](#)
- [FAQs](#)
- [Privacy Policy](#)
- [Terms & Conditions](#)